Instil Bio Inc. (TIL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Instil Bio Inc. stock (TIL) is currently trading at $8.56. Instil Bio Inc. PS ratio (Price-to-Sales) is 55329.79. Analyst consensus price target for TIL is $29.00. WallStSmart rates TIL as Sell.
- TIL PE ratio analysis and historical PE chart
- TIL PS ratio (Price-to-Sales) history and trend
- TIL intrinsic value — DCF, Graham Number, EPV models
- TIL stock price prediction 2025 2026 2027 2028 2029 2030
- TIL fair value vs current price
- TIL insider transactions and insider buying
- Is TIL undervalued or overvalued?
- Instil Bio Inc. financial analysis — revenue, earnings, cash flow
- TIL Piotroski F-Score and Altman Z-Score
- TIL analyst price target and Smart Rating
Instil Bio Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Instil Bio Inc. (TIL) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Instil Bio Inc. (TIL) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
65.83% held by institutions, strong professional interest
Supporting Valuation Data
Instil Bio Inc. (TIL) Areas to Watch (3)
Company is destroying shareholder value
Very expensive at 55329.8x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Instil Bio Inc. (TIL) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 2 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.48) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (55329.79) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -50.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -50.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TIL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TIL's Price-to-Sales ratio of 55329.79x sits near its historical average of 55329.79x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 55329.79x set in Mar 2026, and 0% above its historical low of 55329.79x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Instil Bio Inc. (TIL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Instil Bio Inc. operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -11M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.05, so expect amplified moves relative to the broader market.
Debt management: total debt of 85M is significantly higher than cash (6M). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Instil Bio Inc..
Bottom Line
Instil Bio Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:02:13 AM
About Instil Bio Inc.(TIL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer patients. The company is headquartered in Dallas, Texas.